Candesartan in heart failure

References

• AdamsKFLindenfeldJArnoldJMO2006Executive Summary: HFSA 2006 Comprehensive heart failure practice guidelineJ Cardiac Failure121038
   PubMed Web of Science ®Google Scholar
• AghababianRV2002Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency departmentRev Cardiovasc Med3suppl 4S3912439425
   PubMedGoogle Scholar
• [ACC–AHA] American College of Cardiology–American Heart Association2005Guideline update for the diagnosis and management of chronic heart failure in the adultCirculation112182552
   Web of Science ®Google Scholar
• [AHA] American Heart Association2006Heart disease and stroke statistics – 2006 updateDallasAHA
   Google Scholar
• BartBAErtlGHeldP1999Contemporary management of patients with left ventricular systolic dysfunction: Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) RegistryEur Heart J2011829010448027
   PubMed Web of Science ®Google Scholar
• BiollazJBrunnerHRGavrasI1982Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockadeJ Cardiovasc Pharmacol4966726185790
   PubMed Web of Science ®Google Scholar
• ButerHNavisGYWoittiezAJJ1999Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal functionEur J Clin Pharmacol54953810192757
   PubMed Web of Science ®Google Scholar
• [CHARM-Added] McMurrayJJVOstergrenJSwedbergK2003Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitorsLancet3627677113678869
   PubMed Web of Science ®Google Scholar
• [CHARM-Alternative] GrangerCBMcMurrayJJVYusufS2003Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitorsLancet362772613678870
   PubMed Web of Science ®Google Scholar
• [CHARM-Overall] PfefferMASwedbergKGrangerCB2003Effects of candesartan on mortality and morbidity in patients with chronic heart failureLancet3627596613678868
   PubMed Web of Science ®Google Scholar
• [CHARM-Preserved] YusufSPfefferMASwedbergK2003Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fractionLancet3627778113678871
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGfor the Valsartan Heart Failure Study Group2001A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failureN Engl J Med34516677511759645
   PubMed Web of Science ®Google Scholar
• d’AmoreABlackJMThomasWG2005The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophyHypertension4613475416286564
   PubMed Web of Science ®Google Scholar
• DelgadoRMWillersonJT1999Pathophysiology of heart failure: a look at the futureTex Heart Inst J26283310217468
   PubMed Web of Science ®Google Scholar
• de ZeeuwDRemuzziGKirchW1997Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairmentJ Hum Hypertens11suppl 2S37429331004
   PubMed Web of Science ®Google Scholar
• DostalDE2000The cardiac rennin-angiotensin system: Novel signaling mechanisms related to cardiac growth and functionRegul Pept9111110967197
   PubMedGoogle Scholar
• EasthopeSEJarvisB2002Candesartan cilexetil: an update of its use in essential hypertensionDrugs6212538712010090
   PubMed Web of Science ®Google Scholar
• FarrellDMWeiCCTallajJ2001Angiotensin II modulates catecholamine release into interstitial fluid of canine myocardium in vivoAm J Physiol Heart Circ Physiol281H8132211454586
   PubMed Web of Science ®Google Scholar
• FlatherMDYusufSKøberL2000Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patientsLancet35515758110821360
   PubMed Web of Science ®Google Scholar
• FrancisGSWilson TangWHSonneblickEH2004Pathophysiology of heart failureFusterVAlexanderRWO’RourkeRAHurst’s: the heart11th edNew YorkMcGraw-Hill[online] Accessed 18 March 2006. URL: http//www.accessmedicine.com/
   Google Scholar
• GargRYusufF1995Overview of randomized trials of angiotensin-converting enzyme inhibitors on morbidity and mortality in heart failureJAMA2731450567654275
   PubMed Web of Science ®Google Scholar
• GrangerCBErtlGKuchJ2000Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting-enzyme inhibitorsA Heart J13960717
   Web of Science ®Google Scholar
• GrangerCBSwedbergKEdmanI2005Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomized, controlled clinical trialLancet36620051116338449
   PubMed Web of Science ®Google Scholar
• [HFSA] Heart Failure Society of America20062006 Guideline executive summaryJ Card Fail22006121038
   Google Scholar
• HoogkamerJFWKleinbloesemCHOuwerkerkM1998Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver functionEur J Clin Pharmacol54341459696961
   PubMed Web of Science ®Google Scholar
• HübnerRHögemannAMSunzelM1997Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteersJ Hum Hypertens11suppl 2S1925
   PubMed Web of Science ®Google Scholar
• JessupMBrozenaS2003Heart failureN Engl J Med34820071812748317
   PubMed Web of Science ®Google Scholar
• JordeUPEnnezatPVLiskerJ2000Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failureCirculation101844610694521
   PubMed Web of Science ®Google Scholar
• KimsIwaoH2000Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseasesPharmacol Rev52113410699153
   PubMed Web of Science ®Google Scholar
• LévyBI2004Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin systemCirculation10981314707017
   PubMed Web of Science ®Google Scholar
• KasamaSToyamaTKumaduraH2005Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fractionJ Am Coll Cardiol45661715734608
   PubMed Web of Science ®Google Scholar
• LittleWCWesley-FarringtonDJJoyleJ2004Effect of candesartan and verapamil on exercise tolerance in diastolic dysfunctionJ Cardiovasc Pharmacol432889314716219
   PubMed Web of Science ®Google Scholar
• MitrovicVWillenbrockRMiricM2003Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failureA Heart J145e14
   Web of Science ®Google Scholar
• McKelvieRSYusufSPericadD1999Comparison of candesartan, enalapril, and their combination in congestive heart failure: the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot studyCirculation10010566410477530
   PubMed Web of Science ®Google Scholar
• [MERIT-HF] MERIT-HF Study Group1999Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)Lancet3532001710376614
   PubMed Web of Science ®Google Scholar
• MitrovicVWillenbrockRMiricM2003Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failureAm Heart J145e1412660683
   PubMed Web of Science ®Google Scholar
• NishikawaKNakaTChataniF1997Candesartan cilexetil: a review of its preclinical pharmacologyJ Hum Hypertens11suppl 2S917
   PubMed Web of Science ®Google Scholar
• O’MearaESolomonSMcMurrayJ2004Effect of candesartan on New York Heart Association functional class: Results of the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) ProgramEur Heart J251920615522471
   PubMed Web of Science ®Google Scholar
• OttossonPAttmanPÂgrenA2003Candesartan cilexetil in haemodialysis patientsClin Drug Invest2354550
   Web of Science ®Google Scholar
• PackerMBristowMRCohnJNUS Carvedilol Heart Failure Study Group1996The effect of carvedilol on morbidity and mortality in patients with chronic heart failureN Engl J Med3341349558614419
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVVelazquezEJValsartan in Acute Myocardial Infarction Trial Investigators2003Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both (VALIANT)N Engl J Med349189390614610160
   PubMed Web of Science ®Google Scholar
• PittBRemmeWZannadF2003Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarctionN Engl J Med34813092112668699
   PubMed Web of Science ®Google Scholar
• PittBSegalRMartinezFA1997Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study: ELITE)Lancet349747529074572
   PubMed Web of Science ®Google Scholar
• PittBZannadFRemmeWJ1999The effect of spironolactone on morbidity and mortality in patients with severe heart failureN Engl J Med3417091710471456
   PubMed Web of Science ®Google Scholar
• RichM1997Epidemiology, pathophysiology, and etiology of congestive heart failure in older adultsJ Am Geriatr Soc45968749256850
   PubMed Web of Science ®Google Scholar
• SolomonSDWangDFinnP2004Effect of candesartan on cause-specific mortality in heart failure patients: The Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) ProgramCirculation1102180315466644
   PubMed Web of Science ®Google Scholar
• RiddellJG1997Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetilJ Hum Hypertens11suppl 2S29309331002
   PubMed Web of Science ®Google Scholar
• UrataHHealyBStewartRW1990Angiotensin II-forming pathways in normal and failing human heartsCirc Res66883902156635
   PubMed Web of Science ®Google Scholar
• [FDA] US Food and Drug Administration2006aCandesartan cilexetil, Atacand®: clinical pharmacology and biopharmaceutics review [online]Accessed 18 March 2006. URL: http://www.fda.gov/ohrms/dockets/ac/02/briefing/3877B1_04_FDA-Biopharm.htm
   Google Scholar
• [FDA] US Food and Drug Administration2006bCandesartan cilexetil, Atacand: Label revision, February 22, 2005Accessed 18 April 2006. URL: http://www.fda.gov/cder/foi/label/2006/020838s026lbl.pdf
   Google Scholar
• van LierJJvan HieningenPNSunzelM1997Absorption, metabolism, and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteersJ Hum Hypertens11suppl 2S2789331001
   PubMed Web of Science ®Google Scholar
• VolpeMMusumeciBPaolisPD2003Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular diseaseJ Hypertens2114294312872031
   PubMed Web of Science ®Google Scholar
• WaagsteinFBristowMRSwedbergKfor the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group1993Beneficial Effects of Metoprolol in Idiopathic Dilated CardiomyopathyLancet342144167902479
   PubMed Web of Science ®Google Scholar
• WeberKT2001Aldosterone in congestive heart failureN Engl J Med34516899711759649
   PubMed Web of Science ®Google Scholar
• WiddopREJonesESHannanRE2003Angiotensin AT2 receptors: cardiovascular hope or hype?Br J Pharmacol1408092414530223
   PubMed Web of Science ®Google Scholar
• WillersonJT1995Other cardiomyopathiesWillersonJTCohnJNCardiovascular medicineNew YorkChurchill Livingstone88894
   Google Scholar